AR065312A1 - Nuevos anticuerpos - Google Patents

Nuevos anticuerpos

Info

Publication number
AR065312A1
AR065312A1 ARP080100598A ARP080100598A AR065312A1 AR 065312 A1 AR065312 A1 AR 065312A1 AR P080100598 A ARP080100598 A AR P080100598A AR P080100598 A ARP080100598 A AR P080100598A AR 065312 A1 AR065312 A1 AR 065312A1
Authority
AR
Argentina
Prior art keywords
cdr
seq
amino acid
higf
antigen binding
Prior art date
Application number
ARP080100598A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR065312A1 publication Critical patent/AR065312A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se refiere a preparaciones de anticuerpo que comprenden anticuerpos o fragmentos de union al antígeno de los mismos que se unen específicamente a IGF-1R que comprenden la CDR H3 de la SEC ID N°:1 o una variante de la misma que contiene una o dos sustituciones de aminoácidos en la CDRH3. Se proporciona un anticuerpo o un fragmento de union al antígeno del mismo que se une específicamente a IGF-1R específicamente hIGF-1R y neutraliza la actividad de hIGF-1R, que comprende un dominio variable de cadena pesada que comprende la CDR H3 de la SEC ID N° 1 o variantes de la misma en las que uno o dos restos de aminoácidos dentro de la CDR H3 difieren de los restos de aminoácidos en la posicion correspondiente en la SEC ID N° 1. También composiciones que comprenden dichas preparaciones de anticuerpo y procedimientos para producirla y usos de las mismas.
ARP080100598A 2007-02-14 2008-02-12 Nuevos anticuerpos AR065312A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0702888.9A GB0702888D0 (en) 2007-02-14 2007-02-14 Novel Antibodies
US95321007P 2007-08-01 2007-08-01

Publications (1)

Publication Number Publication Date
AR065312A1 true AR065312A1 (es) 2009-05-27

Family

ID=37908642

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100598A AR065312A1 (es) 2007-02-14 2008-02-12 Nuevos anticuerpos

Country Status (11)

Country Link
US (1) US20100047243A1 (es)
EP (1) EP2115005A2 (es)
CN (1) CN101657469A (es)
AR (1) AR065312A1 (es)
AU (1) AU2008214647A1 (es)
BR (1) BRPI0808087A2 (es)
CA (1) CA2677621A1 (es)
CL (1) CL2008000441A1 (es)
GB (1) GB0702888D0 (es)
TW (1) TW200848428A (es)
WO (1) WO2008098917A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
HUE026374T2 (en) 2008-12-12 2016-05-30 Boehringer Ingelheim Int Anti-IGF antibody
UY32341A (es) * 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
WO2011090492A1 (en) * 2010-01-19 2011-07-28 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
MX2012009809A (es) 2010-02-23 2012-11-23 Sanofi Sa Anticuerpos anti - integrina alfa2 y sus usos.
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
CN108424451B (zh) * 2011-06-03 2022-09-09 佐马技术有限公司 对TGF-β具有特异性的抗体
JP2015505843A (ja) 2011-12-15 2015-02-26 ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用
EP2631653A1 (en) * 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2018217669A1 (en) * 2017-05-21 2018-11-29 Igf Oncology, Llc An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
CN111044722A (zh) * 2020-01-01 2020-04-21 南京优而生物科技发展有限公司 一种辅助生殖技术用鼠胚试验囊胚细胞染色和计数试剂盒
CN113209272B (zh) * 2020-06-23 2022-02-22 阿耳法猫(杭州)人工智能生物科技有限公司 博来霉素与达卡巴嗪联合用药在制备治疗胆管癌药物中的应用
CN114671949B (zh) * 2022-04-20 2023-04-28 山西农业大学 一种igf1纳米抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12589A (en) * 2001-01-05 2006-06-08 Abgenix Inc Antibodies to insulin-like growth factor i receptor.
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US20050008639A1 (en) * 2003-02-14 2005-01-13 Chervonsky Alexander V. Methods of modulating homing of T cell by interruption of chemokine/chemokine receptor signaling
WO2004087756A2 (en) * 2003-04-02 2004-10-14 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
JP2007535895A (ja) * 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
WO2005016967A2 (en) * 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human igf-1r antibodies
WO2005058967A2 (en) * 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
WO2007000328A1 (en) * 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
EP1999149A4 (en) * 2006-03-28 2010-01-20 Biogen Idec Inc ANTI-IGF-1R ANTIBODIES AND USES THEREOF
KR20080104160A (ko) * 2006-03-28 2008-12-01 에프. 호프만-라 로슈 아게 항-ｉｇｆ-１ｒ 인간 단일클론 항체 제형

Also Published As

Publication number Publication date
CL2008000441A1 (es) 2008-08-22
GB0702888D0 (en) 2007-03-28
AU2008214647A1 (en) 2008-08-21
TW200848428A (en) 2008-12-16
BRPI0808087A2 (pt) 2013-07-30
WO2008098917A2 (en) 2008-08-21
CA2677621A1 (en) 2008-08-21
CN101657469A (zh) 2010-02-24
EP2115005A2 (en) 2009-11-11
WO2008098917A3 (en) 2008-10-09
US20100047243A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
AR065312A1 (es) Nuevos anticuerpos
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
PE20131209A1 (es) Anticuerpos anti-fap
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
RS52860B (en) ANTI-ILT7 ANTITELO
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
AR083747A1 (es) Anticuerpos anti-il-23
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20131400A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
AR075504A1 (es) Moleculas de anticuerpos que tienen especificidad para el ox40 humano
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
AR077111A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
EA200800812A1 (ru) Композиции антитела против cd3
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
AR084315A1 (es) Anticuerpos anti-notch1

Legal Events

Date Code Title Description
FB Suspension of granting procedure